DDNews Top 5 Cancer Stories
SEPTEMBER 2014
 
 
 
 
From DDNews Online:
By Kelsey Kaustinen, DDNews Senior Editor
Cellectar will begin clinically advancing I-131-CLR1404, its cancer-targeting radiopharmaceutical
 
From DDNews Daily News:
By Lloyd Dunlap, DDNews Managing Editor
FDA submission reinforces commitment to addressing significant unmet needs for patients with acute lymphoblastic leukemia, an aggressive cancer with limited treatment options
 
From DDNews Daily News:
By Kelsey Kaustinen, DDNews Senior Editor
Patients receiving both therapies had a median overall survival of 21 months, compared to 10 months in patients receiving sorafenib alone
 
From our September 2014 issue:
By Lloyd Dunlap, DDNews Managing Editor
RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by FDA and EMA
 
From our September 2014 issue:
By Zack Anchors, DDNews Contributing Editor
Ventana signs companion diagnostic test agreements with Merck KGaA and Quintiles
 
 
 
 
 
   
©2014 Old River Publications LLC. All Rights Reserved.
Web site designed and managed by Offenberger & White, Inc..
If you no longer wish to receive DDNEWS mailings, please unsubscribe here.